PubMed ID:
15673800
Public Release Type:
Journal
Publication Year: 2005
Affiliation: Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom. solomon.tesfaye@sth.nhs.uk.
DOI:
https://doi.org/10.1056/NEJMoa032782
Authors:
Tesfaye S,
Chaturvedi N,
Eaton SE,
Ward JD,
Manes C,
Ionescu-Tirgoviste C,
Witte DR,
Fuller JH,
EURODIAB Prospective Complications Study Group
Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk factors for the development of distal symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating in the European Diabetes (EURODIAB) Prospective Complications Study.